Aurobindo Pharma Ltd., headquartered in Hyderabad, India, is a leading global pharmaceutical company founded in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy. It specializes in manufacturing and commercializing generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty products across over 150 countries. The company’s robust portfolio spans key therapeutic areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics, with a growing focus on high-value segments like oncology, biosimilars, and novel drug delivery systems. Operating 29 manufacturing and packaging facilities approved by regulatory bodies like USFDA, UK MHRA, and WHO, Aurobindo is a market leader in semi-synthetic penicillins and among India’s top pharmaceutical companies by revenue, generating USD 3.64 billion in trailing 12-month revenue as of December 2024. Its vertically integrated supply chain, strong R&D capabilities with five research centers, and strategic acquisitions, such as Generis Farmacêutica for $152 million in 2017, drive its global expansion. The company exports to over 155 countries, with ~90% of revenues from international operations, and partners with major firms like AstraZeneca and Pfizer